Other research analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft set a €18.00 ($18.37) target price on shares of MorphoSys in a research note on Monday, October 24th. The Goldman Sachs Group set a €24.00 ($24.49) target price on shares of MorphoSys in a research note on Thursday, August 4th. Finally, Berenberg Bank set a €65.00 ($66.33) target price on shares of MorphoSys in a research note on Thursday, August 4th.
MorphoSys Trading Down 2.3 %
Shares of MOR stock opened at €14.81 ($15.11) on Monday. The firm has a 50-day moving average price of €19.36 and a 200 day moving average price of €19.78. MorphoSys has a twelve month low of €13.90 ($14.18) and a twelve month high of €38.11 ($38.89). The company has a market capitalization of $505.64 million and a price-to-earnings ratio of -0.86. The company has a current ratio of 3.76, a quick ratio of 3.49 and a debt-to-equity ratio of 231.51.
MorphoSys Company Profile
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.